Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471510 | 0.98 | CYP1A2 (0.83) | CYP1A2ALDH1A1ALOX15CYP3A4TSHR | |
| SCHEMBL4925671 | 0.98 | CYP1A2 (0.83) | CYP1A2ALDH1A1ALOX15CYP3A4TSHR | |
| SCHEMBL1463911 | 0.98 | CYP1A2 (0.83) | CYP1A2ALDH1A1ALOX15CYP3A4TSHR | |
| SCHEMBL7547097 | 0.98 | CYP1A2 (0.83) | CYP1A2ALDH1A1ALOX15CYP3A4TSHR | |
| SCHEMBL4915851 | 0.98 | CYP1A2 (0.83) | CYP1A2ALDH1A1ALOX15CYP3A4TSHR | |
| SCHEMBL2967294 | 0.98 | CYP1A2 (0.83) | CYP1A2ALDH1A1ALOX15CYP3A4TSHR | |
| SCHEMBL3284074 | 0.98 | CYP1A2 (0.83) | CYP1A2ALDH1A1ALOX15CYP3A4TSHR | |
| SCHEMBL4915881 | 0.98 | CYP1A2 (0.83) | CYP1A2ALDH1A1ALOX15CYP3A4TSHR | |
| SCHEMBL4915709 | 0.98 | CYP1A2 (0.83) | CYP1A2ALDH1A1ALOX15CYP3A4TSHR | |
| SCHEMBL4919758 | 0.98 | CYP1A2 (0.83) | CYP1A2ALDH1A1ALOX15CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943084-A1 | NEP INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | Novartis AG (CH) | 2022-01-26 | — | — | EP | claimed |
| CN-108685889-A | Nep inhibitor for treating the disease for being characterized as atrial enlargement or reconstruct | 诺华股份有限公司 | 2018-10-23 | — | — | CN | claimed |
| EP-3194538-A1 | DISPERSANT VISCOSITY MODIFIERS WITH AMINE FUNCTIONALITY | The Lubrizol Corporation (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2016044254-A1 | DISPERSANT VISCOSITY MODIFIERS WITH AMINE FUNCTIONALITY | THE LUBRIZOL CORPORATION (US) | 2016-03-24 | — | — | WO | claimed |
| CN-101516831-B | Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in production of NEP inhibitors | NOVARTIS AG | 2013-12-25 | — | — | CN | claimed |
| EP-1951309-A2 | COMBINATION OF AN ANGIOTENSIN II RECEPTOR BLOCKER, A CALCIUM CHANNEL BLOCKER AND ANOTHER ACTIVE AGENT | Novartis AG (CH) | 2008-08-06 | — | — | EP | claimed |
| WO-2007056324-A2 | COMBINATION OF AN ANGIOTENSIN II RECEPTOR BLOCKER, A CALCIUM CHANNEL BLOCKER AND ANOTHER ACTIVE AGENT | NOVARTIS AG (CH) | 2007-05-18 | — | — | WO | claimed |
| EP-0308339-B1 | PROCESS FOR THE INDUSTRIAL PREPARATION OF PERHYDROINDOLE -2(2S,3AS,7AS)-CARBOXYLIC ACID, USE IN THE PREPARATION OF CARBOXYALKYL DIPEPTIDES | ADIR ET COMPAGNIE (FR) | 1992-05-06 | — | — | EP | claimed |
| EP-0308339-A1 | Process for the industrial preparation of perhydroindole -2(2S,3aS,7aS)-carboxylic acid, use in the preparation of carboxyalkyl dipeptides | ADIR ET COMPAGNIE (FR) | 1989-03-22 | — | — | EP | claimed |
| US-20250325518-A1 | USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN | NOVARTIS AG (CH) | 2025-10-23 | — | — | US | disclosed |
| EP-4609912-A2 | NEW USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN | Novartis AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| EP-4570314-A2 | SACUBITRIL-VALSARTAN DOSAGE REGIMEN FOR TREATING CHRONIC SYSTOLIC HEART FAILURE | Novartis AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| EP-3411021-B1 | NEW USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN | NOVARTIS AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| EP-4212152-B1 | SACUBITRIL-VALSARTAN DOSAGE REGIMEN FOR TREATING CHRONIC SYSTOLIC HEART FAILURE | NOVARTIS AG (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-4431649-A | TRANQUILIZERS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4427679-A | TRANQUILIZERS; PSYCHOLOGICAL DISORDERS | PFIZER INC. (US) | 1984-01-24 | — | — | US | disclosed |
| EP-0060610-A1 | Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents | PFIZER INC. (US) | 1982-09-22 | — | — | EP | disclosed |
| US-4337250-A | NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1982-06-29 | — | — | US | disclosed |
| US-4054569-A | CNS DEPRESSANTS, ANTICONVULSIVES, ANTIINFLAMMATORY | AYERST MCKENNA & HARRISON LTD. (CA) | 1977-10-18 | — | — | US | disclosed |
| US-3985751-A | CNS DEPRESSANTS, ANTICONVULSANT AND ANTIINFLAMMATORY AGENTS | AYERST MCKENNA AND HARRISON LTD. (CA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325518-A1 | USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN | MME, ACE, REN | CYP1A2 1635/4885ALDH1A1 1449/4885ALOX15 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.